According to CNBC, Sanofi's supply disruption for its Pompe disease medication is ongoing, with some infusion treatments for U.S. patients canceled or delayed due to shipping bottlenecks. The company stated that the impact could extend through late November. Sanofi attributed the shortage to manufacturing compliance remediation at its plant in Ireland, emphasizing that product quality is uncompromised and supply has begun to recover in certain countries. The report did not provide a definitive date for a full recovery, and it should not be inferred that all regions are experiencing complete stockouts or that the drug has been recalled.